a. 140 patients who received favipiravir only or with any other drugs b. Among patients who received favipiravir with any other drugs, comparison between time to admission within 4 days and >4 daysFigure 1. Summary of patients clinical presentation, risk factors*, and initial antiviral treatment.*Risk factors include age >60 years or < 5 years, obesity defined as BMI>35 kg/M2, or other conditions that may be associated with severe COVID-19 illness such as immunocompromised conditions, diabetes, chronic conditions of lungs, kidney, liver, cardiovascular or cerebrovascular diseases, total lymphocyte counts <1,000 cells/mm3. Abbreviation: CQ: chloroquine, HCQ: hydroxychloroquine, bPI: boosted protease inhibitor (ritonavir boosted lopinavir or darunavir), FPV: favipiravir